A Multicenter, Open-label, Randomized, Controlled, Two-arm Study to Assess Compliance With Daily Tablet Intake of Women on Treatment With the Oral Contraceptive SH T00186D/BAY 86-5300 (0.02 mg Ethinyl Estradiol as Betadex Clathrate and 3 mg Drospirenone) in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function Over 12 Months.
Phase of Trial: Phase III
Latest Information Update: 25 Sep 2013
At a glance
- Drugs Drospirenone/ethinylestradiol (Primary)
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Bayer
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Sep 2011 Planned end date changed from 1 Sep 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.
- 27 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.